Skip to main content
Article thumbnail
Location of Repository

Role of TGF-β on cardiac structural and electrical remodeling

By Roberto Ramos-Mondragón, Carlos A Galindo and Guillermo Avila


The type β transforming growth factors (TGF-βs) are involved in a number of human diseases, including heart failure and myocardial arrhythmias. In fact, during the last 20 years numerous studies have demonstrated that TGF-β affects the architecture of the heart under both normal and pathological conditions. Moreover, TGF-β signaling is currently under investigation, with the aim of discovering potential therapeutic roles in human disease. In contrast, only few studies have investigated whether TGF-β affects electrophysiological properties of the heart. This fact is surprising since electrical remodeling represents an important substrate for cardiac disease. This review discusses the potential role of TGF-β on cardiac excitation-contraction (EC) coupling, action potentials, and ion channels. We also discuss the effects of TGF-β on cardiac development and disease from structural and electrophysiological points of view

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2002). Aging-related increase to inducible atrial fi brillation in the rat model.
  2. (2007). Altered expression of FHL1, CARP, TSC-22 and P311 provide insights into complex transcriptional regulation in pacing-induced atrial fi brillation. Biochim Biophys Acta,
  3. (2007). Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.
  4. (1999). Angiotensin II-induced transactivation of epidermal growth factor receptor regulates fi bronectin and transforming growth factor-beta synthesis via transcriptional and posttranscriptional mechanisms. Circ Res,
  5. (2005). Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res,
  6. (2007). Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fi brillation. Physiol Rev,
  7. (2000). Atrial but not ventricular fi brosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. Circ Res,
  8. (1998). Atrial electrophysiologic remodeling: another vicious circle?
  9. (1999). Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fi brillation. Cardiovasc Res,
  10. (1995). Atrial fi brillation begets atrial fi brillation. A study in awake chronically instrumented goats.
  11. (2008). Atrial fi brosis: mechanisms and clinical relevance in atrial fi brillation.
  12. (2007). Atrial glutathione content, calcium current, and contractility.
  13. (2008). Atrial remodeling and atrial fi brillation, mechanisms and implications. Circ Arrhythmia Electrophysiol,
  14. (1996). Autocrine and paracrine regulation of myocardial cell growth in vitro. The TGFβ paradigm. Trends Cardiovasc Med,
  15. (1999). Ca channels in cardiac myocytes: structure and function in Ca infl ux and intracellular Ca release. Cardiovasc Res,
  16. (2002). Cardiac channelopathies.
  17. (2002). Cardiac excitation-contraction coupling.
  18. (2002). Cellular electrophysiologic properties of old canine atria provide a substrate for arrhythmogenesis. Cardiovasc Res,
  19. (1999). Changes in the mRNA levels of delayed rectifi er potassium channels in human atrial fi brillation.
  20. (1995). Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fi brillation.
  21. (1997). Defective excitationcontraction coupling in experimental cardiac hypertrophy and heart failure.
  22. (2002). Density and function of inward currents in right atrial cells from chronically fi brillating canine atria. Cardiovasc Res,
  23. (2004). Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res,
  24. (2008). Differential behaviors of atrial versus ventricular fi broblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences.
  25. (1990). Differentiation repertoire of fi broblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations.
  26. (1999). Dilated cardiomyopathy is associated with signifi cant changes
  27. (2001). Double-outlet right ventricle and overriding tricuspid valve refl ect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice.
  28. (1991). Effect of norepinephrine on myocardial collagen gene expression and response of cardiac fi broblast after norepinephrine treatment.
  29. (2003). Electrical remodeling in cardiac hypertrophy. Trends Cardiovasc Med,
  30. (1999). Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res,
  31. (1989). Epithelial-mesenchymal cell transformation in the embryonic heart can be mediated, in part, by transforming growth factor beta. Dev Biol,
  32. (2001). Excitation-contraction coupling and cardiac contractile force. Series: Developments
  33. (2001). Functional role of TGF beta in Alzheimer’s disease microvascular injury: lessons from transgenic mice. Neurochem Int,
  34. (2002). Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev,
  35. (2005). Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fi brillation.
  36. (1991). In situ localization of transforming growth factor beta 1 in porcine heart: enhanced expression after chronic coronary artery constriction.
  37. (2004). Increased vulnerability to atrial fi brillation in transgenic mice with selective atrial fi brosis caused by overexpression of TGF-beta 1. Circ Res,
  38. (2005). Inherited and acquired vulnerability to ventricular arrhythmias: Cardiac Na+ and K+ channels. Physiol Rev,
  39. (2000). Interaction between angiotensin II and Smad proteins in fi broblasts in failing heart and in vitro.
  40. (2005). Intracellular calcium release and cardiac disease. Annu Rev Physiol,
  41. (2001). Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fi brillation.
  42. (1996). Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res,
  43. (2004). L-type Ca2+ current downregulation in chronic human atrial fi brillation is associated with increased activity of protein phosphatases.
  44. (2000). Mechanisms involved in valvuloseptal endocardial cushion formation in early cardiogenesis: roles of transforming growth factor (TGF)-beta and bone morphogenetic protein (BMP). Anat Rec,
  45. (2008). Mechanisms of fi brogenesis.
  46. (2008). Mechanisms of perpetuation of atrial fi brillation in chronically dilated atria. Prog Biophys Mol Biol,
  47. (2001). Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fi brillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials.
  48. (1999). Molecular mechanisms underlying ionic remodeling in a dog model of atrial fi brillation. Circ Res.
  49. (2000). Myocardial fi brosis in transforming growth factor β1 heterozygous mice.
  50. (1997). Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic cardiomyopathy.
  51. (2002). p38 mitogen-activated protein kinase is required for TGFbeta-mediated fi broblastic transdifferentiation and cell migration.
  52. (1990). Peptide growth factors can provoke “fetal” contractile protein gene expression in rat cardiac myocytes.
  53. (2007). Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fi brillation. Arch Pharmacol,
  54. (2003). Pharmacological prevention of atrial tachycardia induced atrial remodeling as a potential therapeutic strategy. Pacing Clin Electrophysiol,
  55. (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.
  56. (2006). Pirfenidone prevents the development of a vulnerable substrate for atrial fi brillation in a canine model of heart failure.
  57. (2005). Postinfarction gene therapy against transformig growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure.
  58. (2008). Pro-oxidant effect of transforming growth factor-β1 mediates contractile dysfunction in rat ventricular myocytes. Cardiovasc Res,
  59. (1999). Promotion of atrial fi brillation by heart failure in dogs: atrial remodeling of a different sort.
  60. (2005). Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta- preprogrammed bone marrow stem cells.
  61. (2005). Regulatory mutations in transforming growth factor-beta3 gene cause arrhytmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res,
  62. (1999). Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart.
  63. (1992). Role of transforming growth factor-β in maintenance of function of cultured neonatal cardiac myocytes. Autocrine action and reversal of myocytes.
  64. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling.
  65. (1998). Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases.
  66. (1999). Specifi city, diversity, and regulation in TGF-beta superfamily signaling.
  67. (1999). Structure and function of cardiac potassium channels. Cardiovasc Res,
  68. (1999). Structure and function of the cardiac sodium channels. Cardiovasc Res,
  69. (2000). Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol,
  70. (2007). TGF-beta in renal injury and disease. Semin Nephrol,
  71. (2004). TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome.
  72. (2007). TGF-beta-induced EMT: mechanisms and implications for fi brotic lung disease.
  73. (2002). TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II.
  74. (1998). TGF-beta1 up-regulates the mRNA for the Na+/Ca2+ exchanger in neonatal rat cardiac myocytes. Cell Mol Biol,
  75. (2003). TGF-beta1-mediated fi broblast-myofi broblast terminal differentiation-the role of Smad proteins. Exp Cell Res,
  76. (2004). TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res,
  77. (2008). TGF-β1 chronically regulates voltage-gated sodium and potassium channels in neonatal rat atrial myocytes. Long Beach, CA: Annual Meeting of the Biophysical Society.
  78. (1999). TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev Biol,
  79. (1997). TGFbeta2 knockout mice have multiple developmental defects that are nonoverlapping with other TGFbeta knockout phenotypes.
  80. (2007). The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res,
  81. (2003). The two faces of transforming growth factor beta in carcinogenesis.
  82. (2002). Therapeutic implications of atrial fi brillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res,
  83. (1988). Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors,
  84. (2005). Transforming growth factor β-1 downregulates beating frequency and remodeling of cultured rat adult cardiomyocytes. Cell Tissue Res,
  85. (1993). Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofi broblasts and in quiescent and growing cultured fi broblasts.
  86. (2002). Transforming growth factor-beta function blocking prevents myocardial fi brosis and diastolic dysfunction in pressure-overloaded rats.
  87. (2007). Transforming growth factor-β1 decreases cardiac muscle L-type Ca2+ current and charge movement by acting on the Cav1.2 mRNA.
  88. (1994). Transforming growth factor-β1 regulates the expression of ryanodine-sensitive Ca2+ oscillations in cardiac myocytes.
  89. (2004). Transforming growth factorbeta-induced transition of fi broblasts: a model for myofi broblast procurement in tissue valve engineering. J Heart Valve Dis,
  90. (2001). Update on atrial remodelling owing to rate; does atrial fi brillation always ‘beget’ atrial fi brillation? Eur Heart J,
  91. (1997). Upregulation of expression of sarcoplasmic reticulum by TGF-β1 in cultured rat cardiac myocytes.
  92. (1979). Use of chlorotetracycline fl uorescence to demonstrate Ca2+-induced release of Ca2+ from the sarcoplasmic reticulum of skinned cardiac cells.
  93. (2004). Valvular myofi broblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res,
  94. (2005). Yin and Yang of myocardial transforming growth factor-beta1: timing is everything.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.